TY  - JOUR
AU  - Lozano, Rebeca
AU  - Castro, Elena
AU  - Aragon, Isabel M
AU  - Cendon, Ylenia
AU  - Cattrini, Carlo
AU  - Lopez-Casas, Pedro P
AU  - Olmos, David
PY  - 2020
DO  - 10.1038/s41416-020-01114-x
UR  - http://hdl.handle.net/10668/16483
T2  - British journal of cancer
AB  - Over the past years, several studies have demonstrated that defects in DNA damage response and repair (DDR) genes are present in a significant proportion of patients with prostate cancer. These alterations, particularly mutations in BRCA2, are known...
LA  - en
PB  - Springer Nature
KW  - Genes, BRCA1
KW  - Genes, BRCA2
KW  - Ataxia telangiectasia mutated proteins
KW  - Clinical trials as topic
KW  - Antineoplastic agents
KW  - Ataxia telangiectasia mutated proteins
KW  - Clinical trials as topic
KW  - DNA damage
KW  - DNA repair
KW  - Genes, BRCA1
KW  - Genes, BRCA2
KW  - Germ-line mutation
KW  - High-Throughput nucleotide sequencing
KW  - Humans
KW  - Immune checkpoint inhibitors
KW  - Indazoles
KW  - Indoles
KW  - Male
KW  - Phthalazines
KW  - Piperazines
KW  - Piperidines
KW  - Platinum compounds
KW  - Poly(ADP-ribose) polymerase inhibitors
KW  - Precision medicine
KW  - Prognosis
KW  - Prostatic neoplasms
TI  - Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
TY  - research article
VL  - 124
ER  -